Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2023), 37, 6, (1242-1248), 10.1038/s41433-022-02092-5)

David R. Lally; Anat Loewenstein; Jennifer J. Arnold; Yit C. Yang; Kinfemichael Gedif; Catherine Best; Hersh Patel; Ramin Tadayoni; Jeffrey S. Heier

doi:10.1038/s41433-022-02130-2

Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2023), 37, 6, (1242-1248), 10.1038/s41433-022-02092-5)

David R. Lally^*, Anat Loewenstein, Jennifer J. Arnold, Yit C. Yang, Kinfemichael Gedif, Catherine Best, Hersh Patel, Ramin Tadayoni, Jeffrey S. Heier

^*Corresponding author for this work

Ophthalmology

Research output: Contribution to journal › Comment/debate

Abstract

With

Original language	English
Pages (from-to)	1748
Number of pages	1
Journal	Eye (Basingstoke)
Volume	37
Issue number	8
DOIs	https://doi.org/10.1038/s41433-022-02130-2
State	Published - Jun 2023

Access to Document

10.1038/s41433-022-02130-2

Fingerprint

Dive into the research topics of 'Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2023), 37, 6, (1242-1248), 10.1038/s41433-022-02092-5)'. Together they form a unique fingerprint.

Cite this

Lally, D. R., Loewenstein, A., Arnold, J. J., Yang, Y. C., Gedif, K., Best, C., Patel, H., Tadayoni, R., & Heier, J. S. (2023). Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2023), 37, 6, (1242-1248), 10.1038/s41433-022-02092-5). Eye (Basingstoke), 37(8), 1748. https://doi.org/10.1038/s41433-022-02130-2

@article{2ea20c8e5959411dad7215689b03ad03,

title = "Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2023), 37, 6, (1242-1248), 10.1038/s41433-022-02092-5)",

abstract = "With",

author = "Lally, {David R.} and Anat Loewenstein and Arnold, {Jennifer J.} and Yang, {Yit C.} and Kinfemichael Gedif and Catherine Best and Hersh Patel and Ramin Tadayoni and Heier, {Jeffrey S.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2023",

month = jun,

doi = "10.1038/s41433-022-02130-2",

language = "אנגלית",

volume = "37",

pages = "1748",

journal = "Eye (Basingstoke)",

issn = "0950-222X",

publisher = "Springer Nature",

number = "8",

}

Lally, DR, Loewenstein, A, Arnold, JJ, Yang, YC, Gedif, K, Best, C, Patel, H, Tadayoni, R & Heier, JS 2023, 'Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2023), 37, 6, (1242-1248), 10.1038/s41433-022-02092-5)', Eye (Basingstoke), vol. 37, no. 8, pp. 1748. https://doi.org/10.1038/s41433-022-02130-2

Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2023), 37, 6, (1242-1248), 10.1038/s41433-022-02092-5). / Lally, David R.; Loewenstein, Anat; Arnold, Jennifer J. et al.
In: Eye (Basingstoke), Vol. 37, No. 8, 06.2023, p. 1748.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2023), 37, 6, (1242-1248), 10.1038/s41433-022-02092-5)

AU - Lally, David R.

AU - Loewenstein, Anat

AU - Arnold, Jennifer J.

AU - Yang, Yit C.

AU - Gedif, Kinfemichael

AU - Best, Catherine

AU - Patel, Hersh

AU - Tadayoni, Ramin

AU - Heier, Jeffrey S.

PY - 2023/6

Y1 - 2023/6

N2 - With

AB - With

UR - http://www.scopus.com/inward/record.url?scp=85131580065&partnerID=8YFLogxK

U2 - 10.1038/s41433-022-02130-2

DO - 10.1038/s41433-022-02130-2

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 35676464

AN - SCOPUS:85131580065

SN - 0950-222X

VL - 37

SP - 1748

JO - Eye (Basingstoke)

JF - Eye (Basingstoke)

IS - 8

ER -

Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2023), 37, 6, (1242-1248), 10.1038/s41433-022-02092-5)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this